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Background: Patients with nonischemic heart failure (HF) are a diverse population with variable response to medical therapy. Subtype 
classification may provide insight into key disease mechanisms and have implications for prognosis and response to medical therapy. Latent class 
analysis (LCA) is a novel statistical approach for subtype identification.
Methods: 1121 patients with nonischemic HF were selected from the Beta-Blocker Evaluation of Survival Trial which randomized New York Heart 
Association Class III/IV patients with a left ventricular ejection fraction (EF) ≤ 35% to bucindolol vs. placebo. Patients were ranked according to 30 
clinical features. LCA was applied to 16 features to identify subtypes of HF and 14 features to identify HF stages. Outcomes were all-cause mortality, 
sudden death, and improvement in EF ≥ 10% within 12 months of randomization.
Results: 6 subtypes and 5 stages were identified. Both HF type and stage were associated with significant differences in outcomes. HF stage 
identified patients at highest risk of sudden death at 1 year with a range of 4.5% to 32.4%, while type was associated with a wider range of response 
to bucindolol with an odds ratio range of 1.34-8.04.
Conclusions: High-dimensional clinical characterization of HF patients is useful in identifying subtypes and stage of HF which predict both adverse 
outcomes and response to bucindolol. Features of these classes may provide insight into disease mechanisms and opportunities for targeted 
intervention. 
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1 99 109 19.2 17.4 0.91 (0.81-1.02) 17.2 12.8 0.75 (0.66-0.85) 21.2 28.4 1.34 (1.22-1.47)
2 74 87 2.7 2.3 0.85 (0.55-1.32) 2.7 2.3 0.85 (0.55-1.32) 28.4 37.9 1.34 (1.21-1.48)
3 103 83 11.7 4.8 0.41 (0.33-0.51) 6.8 4.8 0.71 (0.55-0.90) 13.6 37.3 2.75 (2.47-3.07)
4 89 73 15.7 12.3 0.78 (0.66-0.93) 10.1 9.6 0.95 (0.77-1.16) 19.1 27.4 1.43 (1.27-1.62)
5 45 42 11.1 11.9 1.07 (0.75-1.52) 6.7 11.9 1.20 (1.29-2.72) 4.4 35.7 8.04 (5.72-12.17)
6 153 164 7.2 3.7 0.51 (0.44-0.59) 6.5 2.4 0.31 (0.44-0.47) 26.4 50.6 1.94 (1.85-2.03)
HF stage
1 68 63 10.3 9.5 0.93 (0.77-1.11) 7.4 7.9 1.08 (0.88-1.33) 14.7 28.6 1.94 (1.73-2.19)
2 194 185 7.7 3.2 0.42 (0.38-0.46) 5.7 2.2 0.38 (0.34-0.43) 29.4 53.5 1.82 (1.78-1.87)
3 133 120 8.3 5.0 0.60 (0.54-0.68) 4.5 2.5 0.55 (0.47-0.66) 19.5 37.5 1.92 (1.82-2.02)
4 131 127 13.0 11.0 0.85 (0.78-0.92) 10.7 11.0 1.03 (0.95-1.13) 14.5 26.0 1.79 (1.68-1.91)
5 37 63 35.1 20.6 0.59 (0.51-0.67) 32.4 15.9 0.49 (0.42-0.57) 8.1 28.6 3.52 (2.84-4.50)
